explore -WSS

explore

author：leisure time 2025-10-01 10:57:30 - browse：25329

LONDON — An experimental blood cancer drug from MorphoSys hit its primary target in a pivotal trial, the company announced late Monday, but the drug faltered in addressing patient symptoms, causing the company’s stock to fall in early Tuesday trading.

In the Phase 3 trial, the German company was testing its drug candidate pelabresib combined with the drug Jakafi against a Jakafi-placebo duo in patients with newly diagnosed myelofibrosis, a type of rare blood cancer. Jakafi is a standard myelofibrosis treatment.

The drug combination succeeded on its primary endpoint, with 66% of patients seeing at least a 35% reduction in spleen volume after 24 weeks versus 35% on the placebo regimen — an improvement the company in a release called “statistically significant and clinically meaningful.” Myelofibrosis is a rare bone marrow cancer that causes low blood cell counts and enlarged spleens, so reducing spleen volume is commonly used as the primary efficacy goal in clinical trials.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： Medicare coverage of Wegovy, once blocked, now looks possible

leisure time

WSS

15 die by electrocution after transformer explodes in northern India

Readout Newsletter: CAR

Bayer exec: U.S. is key in reviving beleaguered pharma’s drug pipeline

A strong 6.5

Why scientists need input from humanists on sensitive research

What we know about the American soldier detained in North Korea

leisure time

explore

hotspot

Anesthesiologist group: stop taking Ozempic before surgery

Search resumes for 2 missing children washed away with mom in deadly Pennsylvania flash flood

United colonoscopy coverage change 'may cost lives,' doctors say

Boston's new lab space is opening empty

Apple is now the first public company to be valued at $3 trillion

Readout LOUD podcast: ALS dilemma, first MASH drug, and more

Medical leaders decry Supreme Court decision on affirmative action

John Green on his newest strategy for fighting tuberculosis

BioMarin wins approval for gene therapy to treat hemophilia A

More hospitals are billing patients as online messages surge

hotspot

EPA limits use of carcinogenic gas for sterilizing medical devices

Search resumes for 2 missing children washed away with mom in deadly Pennsylvania flash flood

Study: Hearing aids may slow cognitive decline in those at risk

Amid AI frenzy, a top HHS official's quest to create safeguards

How to save health care price transparency rules

As AI in medicine takes off, can 'human in the loop' prevent harm?

hotspot

leisure time

focus

focus